BSC 1101
Alternative Names: BSC-1101Latest Information Update: 06 Jul 2023
At a glance
- Originator BiSiChem
- Class Analgesics; Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Pain
Most Recent Events
- 27 Jun 2023 BSC 1101 is available for licensing as of 27 Jun 2023. https://www.bisichem.com/default/ (BiSiChem website, June 2023)
- 27 Jun 2023 Early research in Cancer in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)
- 27 Jun 2023 Early research in Pain in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)